The University of Kansas Patent applications |
Patent application number | Title | Published |
20150307837 | REPROGRAMMING OF HUMAN WHARTONS JELLY CELLS TO PRODUCE HAIR CELLS - A method of transforming human cells into mechanosensory hair cells (MHCs), such as inner hear hair cells in the cochlea and vestibular organs, can include: causing human Wharton's jelly cells (hWJCs) to increase expression of or biological function of HATH1 so as to transform the hWJCs into MHCs. The method can include; administering a nucleic acid that encodes HATH1 to the hWJCs; causing inhibited expression of or biological function of HES1 and/or HES5 in the hWJCs; administering a nucleic acid that inhibits HES1 and/or a nucleic acid that inhibits HES5 to the hWJCs; causing inhibited expression of or biological function of HES1 and/or HES5 in the WJCs by administering a nucleic acid that inhibits HES1 and/or a nucleic acid that inhibits HES5; nucleic acids are administered includes a sequence of SEQ ID NO: 2, SEQ ID NO: 3, and/or SEQ ID NO: 4. | 10-29-2015 |
20150230918 | BIOMATERIAL BASED ON ALIGNED FIBERS, ARRANGED IN A GRADIENT INTERFACE, WITH MECHANICAL REINFORCEMENT FOR TRACHEAL REGENERATION AND REPAIR - An implant can include a plurality of polymeric fibers associated together into a fibrous body. The fibrous body is capable of being shaped to fit a tracheal defect and capable of being secured in place by suture or by bioadhesive. The fibrous body can have aligned fibers (e.g., circumferentially aligned) or unaligned fibers. The fibrous body can be electrospun. The fibrous body can have a first characteristic in a first gradient distribution across at least a portion of the fibrous body. The fibrous body can include one or more structural reinforcing members, such as ribbon structural reinforcing members, which can be embedded in the plurality of fibers. The fibrous body can include one or more structural reinforcing members bonded to the fibers with liquid polymer as an adhesive, the liquid polymer having a substantially similar composition of the fibers. | 08-20-2015 |
20150217936 | SYSTEM AND METHODS FOR ARCHIVING AND RETRIEVING SPECIMENS - Embodiments of the present invention include a system and methods for archiving and/or retrieving specimens. Embodiments of the system of the present invention include a movement mechanism, an archival structure, and a software program. Embodiments of the device are configured to acquire a specimen, transport the specimen to a unique location in the archival structure, and store information regarding specimen identification and storage location. | 08-06-2015 |
20150190529 | TARGETING MULTIPLE RECEPTORS ON A CELL SURFACE FOR SPECIFIC CELL TARGETING - A method of delivering a cargo agent into cytosol of a cell can include: providing the delivery system of one of the embodiments described herein having the first and second delivery platforms; and administering the delivery system to a cell so as to cause targeting of two features on the cell so as to: cause endocytosis of the first and second delivery platforms of the delivery system into a common endosome, destabilize the endosome of the cell having the delivery system, release the cargo agent from the second linker; and release the cargo agent from the destabilized endosome into cytosol of the cell. A method of treating a disease can include: performing the method of method of delivering a cargo agent into cytosol of a cell in a subject having a disease, wherein the cargo agent is a therapeutic agent for the disease. | 07-09-2015 |
20150183755 | SPRAY OXIDATION PROCESS FOR PRODUCING 2,5-FURANDICARBOXYLIC ACID FROM HYDROXYMETHYLFURFURAL - A process is provided for carrying out an oxidation on a sprayable feed including a furanic substrate to be oxidized and a catalytically effective combination of cobalt, manganese, and bromide components for catalyzing the oxidation of the furanic substrate, which process comprises spraying the feed into a reactor vessel as a mist, supplying an oxidant, reacting the furanic substrate and the oxidant, and managing the exothermic temperature rise due to the reaction through a selection and control of the operating pressure within the reactor vessel. A crude dehydration product from the dehydration of fructose, glucose or both, including 5-hydroxymethylfurfural, can be directly oxidized by the process to produce 2,5-furandicarboxylic acid in surprisingly increased yields. | 07-02-2015 |
20150175725 | MAGNETIC PARTICLE-POLYMER HYBRID MATERIALS WITH FUNCTIONALIZED POLYMERS DERIVED FROM NORBORNENYL REAGENTS - A magnetic particle-polymer hybrid material can include: a substance having a structure of Formula 1 or derivative or salt thereof: Z(L-FP) | 06-25-2015 |
20150151004 | METHODS AND COMPOSITIONS OF MODULATING TUMOR INITIATING CELLS AND THE USE THEREOF - A therapeutic vector can include: a lipid particle; a CD44 antigen targeting moiety associated with the lipid particle; and a therapeutic nucleic acid associated with the lipid particle. The CD44 antigen targeting moiety can be anti-CD44 antibody and/or anti-CD44 scFv. The lipid particle can have a formula according to one of the following: DOTAP/DOPE 1:1 molar ratio; DDAB/DOPE 1:1 molar ratio; DDAB/DOPE 1:2 molar ratio; DOTAP/Chol 1:1 molar ratio; DDAB/Chol 1:1 molar ratio; DOTAP/DOPE/Chol 2:1:1 molar ratio; and DDAB/DOPE/Chol 2:1:1 molar ratio. The molar ratios can range +/−1%, 5%, 10%, or 20%. A method of inhibiting cancer development can include: providing the therapeutic vector and administering the therapeutic vector to the subject in an amount to inhibit cancer development. | 06-04-2015 |
20150111858 | METHOD OF TREATMENT WITH PRODRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4-METHYLPYRIDIN IN-2-1H-ONE AND DERIVATIVES THEREOF - A prodrug can have a structure of Formula 10 or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, cancer, dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, | 04-23-2015 |
20150094216 | SYSTEMS AND METHODS FOR IDENTIFYING PROTEIN STABILIZERS - A device for studying protein conformation transformation can include a macroscopic substrate, and chaperonin proteins bound to the substrate, each chaperonin protein being capable of binding to a protein of interest during or after undergoing protein conformation transformation. The device may also include the proteins of interest bound to the substrate, where the substrate is included in a label-free assay system. A method of studying protein conformation transformation can include: providing a macroscopic substrate bound with the chaperonin protein and immersing the chaperonin protein in a study composition having the protein of interest, or include providing a macroscopic substrate bound with the protein of interest; and immersing the protein in a study composition having the chaperonin. Such a method can be done with and without a potential stabilizer in order to determine whether the potential stabilizer stabilizes the protein of interest. | 04-02-2015 |
20150087549 | METHODS OF USING TISSUE BIOMARKERS FOR INDICATION OF PROGRESSION FROM BARRETTS ESOPHAGUS TO ESOPHAGEAL ADENOCARCINOMA - A method of diagnosing progression from Barrett's esophagus toward esophageal dysplasia can include: obtaining miRNA from a test subject having Barrett's esophagus; assaying for miRNA biomarker selected from one or more of miR-15b or miR-486-5p; and determining whether one or more of miR-15b or miR-486-5p provide an indication of progression toward esophageal dysplasia in the test subject. The method can include determining an amount of one or more of miR-15b or miR-486-5p. The method can include determining a modulation in amount of one or more of miR-15b or miR-486-5p. The method can include comparing the one or more of miR-15b or miR-486-5p with a positive control or a negative control. | 03-26-2015 |
20140343305 | PROCESS FOR PRODUCING BOTH BIOBASED SUCCINIC ACID AND 2,5-FURANDICARBOXYLIC ACID - A process is provided for carrying out an oxidation on a feed including levulinic acid and/or a levulinic acid oxidation precursor to succinic acid, one or more furanic oxidation precursors of 2,5-furandicarboxylic acid and a catalytically effective combination of cobalt, manganese, and bromide components for catalyzing the oxidation of the levulinic acid component and of the one or more furanic oxidation precursors to produce both succinic acid and 2,5-furandicarboxylic acid products, which process comprises supplying the feed to a reactor vessel, supplying an oxidant, reacting the levulinic acid component and the one or more furanic oxidation precursors with the oxidant to produce both succinic acid and 2,5-furandicarboxylic acid (FDCA) and then recovering the succinic acid and FDCA products. A crude dehydration product from the dehydration of fructose, glucose or both, including 5-hydroxymethylfurfural, can be directly oxidized by the process to produce 2,5-furandicarboxylic acid and succinic acid. | 11-20-2014 |
20140219997 | Templated Islet Cells and Small Islet Cell Clusters for Diabetes Treatment - A population of small reaggregated islets or clusters engineered from individual islet cells and having improved characteristics as compared to native isolated islets. | 08-07-2014 |
20140202693 | NANOGELS FOR DELAYED GELATION - The instant application relates to nanogels or compositions that hold multivalent metal ions until some level of nanogel degradation has occurred, then slowly release the multivalent metal ions for gelation with carboxylate containing polymers. Compositions comprising such nanogels, together with polymers that can be crosslinked with multivalent metal ions, allow the deployment of such mixtures in various applications, and greatly increased gelation times. | 07-24-2014 |
20140200678 | BIOMATERIALS WITH MICROSPHERE GRADIENTS AND CORE AND SHELL MICROSPHERES - Methods can prepare tissue engineering scaffolds that include a plurality of biocompatible core/shell microspheres linked together to form a three-dimensional matrix. The matrix can include a plurality of pores for growing cells. The biocompatible microspheres can include first and second sets of microspheres. The first set of microspheres can have a first characteristic, and a first predetermined spatial distribution with respect to the three-dimensional matrix. The second set of microspheres can have a second characteristic that is different from the first characteristic, and a second predetermined spatial distribution that is different from the first predetermined spatial distribution with respect to the three-dimensional matrix. The first and second characteristics can selected a composition, polymer, particle size, particle size distribution, type of bioactive agent, type of bioactive agent combination, bioactive agent concentration, amount of bioactive agent, rate of bioactive agent release, mechanical strength, flexibility, rigidity, color, radiotranslucency, radiopaqueness, or the like. | 07-17-2014 |
20140163528 | MANEUVERABLE NASOENTERIC FEEDING TUBE - A maneuverable feeding tube system can include: a feeding tube having an internal lumen and distal opening; a maneuverable tube having a flexible distal end being located within the internal lumen of the feeding tube such that the flexible distal end is associated with the distal opening of the feeding tube, wherein the flexible distal end includes one or more flex members; a control member operably coupled to a flexible distal end of the maneuverable tube and extending through the internal lumen of the feeding tube; and a port coupled to a proximal end of the feeding tube with the control member extending therethrough. | 06-12-2014 |
20140148915 | GENERATING CK19-POSITIVE CELLS WITH HAIR-LIKE STRUCTURES FROM WHARTONS JELLY - A method of differentiating cells into CK19-positive cells capable of producing hair follicle-like and hair structure-like can include: providing a tissue scaffold; seeding cells into the scaffold, the cells being capable of differentiation; incubating the scaffold having the cells in a cell growth media; and incubating the scaffold having the cells in an osteogenic differentiation medium sufficient for CK19-positive cells to be generated in the scaffold. The tissue scaffold can be a decellularized Whartons' jelly matrix. The cell growth media excludes osteogenic differentiation components: dexamethasone, β-glycerophosphate, 1α,25-hydroxyvitamin D3, and ascorbic acid 2-phosphate. The osteogenic differentiation medium includes the osteogenic differentiation components. The cells can be mesenchymal cells, such as WJMSCs. | 05-29-2014 |
20140088144 | INHIBITING MICROBIAL INFECTIONS - A method of inhibiting a microbial infection can include: providing a compound of the invention or prodrugs or pharmaceutically acceptable salts thereof; and administering the compound to a subject in a therapeutically effective amount to inhibit the microbial infection. The therapeutically effective amount can be sufficient to inhibit a biological activity of a transcriptional activator of the microbe. The inhibited transcriptional activator is an AraC bacterial transcriptional activator. The AraC bacterial transcriptional activator can be RhaS, RhaR, Rns, or VirF. The microbe can be selected from | 03-27-2014 |
20140081050 | SINGLE SOLVENT GAS EXPANDED HYDROFORMYLATION PROCESS - Allyl alcohol, particularly from biobased sources such as glycerol, is hydroformylated to products including 4-hydroxybutyraldehyde and 4-hydroxy-2-methylpropionaldehyde by forming a homogeneous reaction mixture including allyl alcohol, a rhodium-based hydroformylation catalyst and a near critical liquefiable petroleum gas or mixture of such gases, reacting the near critical liquefiable petroleum gas (or gas mixture)-expanded allyl alcohol substrate with carbon monoxide and with hydrogen in the presence of the catalyst, and recovering substantially all of the petroleum gas or gases overhead by reducing the pressure and degassing the product mixture. Dense propane is especially useful as a single inert solvent/diluent, and substantially no other solvent/diluent is needed. | 03-20-2014 |
20140046231 | MEDICAL DEVICE FOR THERAPEUTIC STIMULATION OF THE VESTIBULAR SYSTEM - A method for providing vestibular stimulation includes: providing an infant in a vestibular stimulation device; associating sensors to the infant; moving the vestibular stimulation device to provide vestibular stimulation treatment; and obtaining sensor data during the treatment. The vestibular stimulation device includes a holder member; a platform; a mechanical system coupling the holder member to the platform; sensors configured to detect one or more parameters of the infant; and a computing system having a user input and/or output interface operably coupled to the mechanical system and the sensors to provide mechanical data to the mechanical system in order to control movement of the holder member relative to the platform and to collect the one or more parameters of the living subject from the sensors. | 02-13-2014 |
20140008447 | MICROSTRIP ANTENNA FOR RFID DEVICE HAVING BOTH FAR-FIELD AND NEAR-FIELD FUNCTIONALITY - Microstrip patch antenna ( | 01-09-2014 |
20130319410 | INHALATION DEVICE, SYSTEMS, AND METHODS FOR ADMINISTERING POWDERED MEDICAMENTS TO MECHANICALLY VENTILATED SUBJECTS - Inhalation devices, systems, and methods for the administration of powdered medicaments to mechanically ventilated subjects are provided. In one embodiment, an inhalation device adaptively connected at one end to an air source and at the other end is operatively disposed to a ventilator circuit is provided. The inhalation devices are capable of causing a powdered medicament within a container held by the device to be dispensed from the container into the lungs of a mechanically ventilated subject. | 12-05-2013 |
20130264542 | Multiwall Carbon Nanotube Opto-Electronic Devices - A high-sensitivity detector for opto-electronic detection using multiwall carbon nanotubes (MWCNTs) is provided. More specifically, multiwall carbon nanotube films demonstrate an infrared bolometric photoresponse higher than SWCNT films at room temperature. The observed D* exceeding 3.3×10 | 10-10-2013 |
20130123296 | LONIDAMINE ANALOGUES FOR FERTILITY MANAGEMENT - Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject. | 05-16-2013 |
20130059324 | SYSTEMS AND METHODS FOR MECHANICALLY STRAINED CELL CULTURE - A method for in vitro drug screening can include: providing one or more cells in vitro; introducing a chemical to the one or more cells; introducing a mechanical strain to the one or more cells in the presence of the chemical; and determining whether or not the chemical has bioactivity with respect to the one or more cells under the mechanical strain. The mechanical strain can be implemented with a well plate defining a plurality of cell culture wells and having one or more flexible substrates associated with the well plate so that each cell culture well has a fluid tight flexible cell culture substrate. A dynamic in vitro screening device can include: a top plate defining one or more cell culture wells; one or more flexible cell culture substrates operably coupled with the top plate to form fluid tight cell culture well bottoms; an a pin plate under the top plate with the one or more flexible cell culture substrates therebetween, the pin plate having one or more pin members associated with the one or more cell culture wells. | 03-07-2013 |
20130029875 | TEMPLATED ISLET CELLS AND SMALL ISLET CELL CLUSTERS FOR DIABETES TREATMENT - Substrates and devices for culturing cells are disclosed, along with methods of using the same. The substrates and devices include top surfaces with one or more divots disposed therein. Each divot is defined by an opening in the top surface, a rounded bottom surface spaced from the opening, and an interior side-wall surface extending between the rounded bottom surface and the opening. The top surface of the substrates and devices are optionally walled to form wells containing one or more divots. The substrates and devices may be used for reaggregating cells, for example, to form small islet cell clusters and for high throughput testing methodologies. | 01-31-2013 |
20120313284 | METHODS OF MANUFACTURING BIOMATERIALS WITH MICROSPHERE GRADIENTS - Methods can prepare tissue engineering scaffolds that include a plurality of biocompatible microspheres linked together to form a three-dimensional matrix. The matrix can include a plurality of pores for growing cells. The biocompatible microspheres can include first and second sets of microspheres. The first set of microspheres can have a first characteristic, and a first predetermined spatial distribution with respect to the three-dimensional matrix. The second set of microspheres can have a second characteristic that is different from the first characteristic, and a second predetermined spatial distribution that is different from the first predetermined spatial distribution with respect to the three-dimensional matrix. The first and second characteristics can selected a composition, polymer, particle size, particle size distribution, type of bioactive agent, type of bioactive agent combination, bioactive agent concentration, amount of bioactive agent, rate of bioactive agent release, mechanical strength, flexibility, rigidity, color, radiotranslucency, radiopaqueness, or the like. | 12-13-2012 |
20120294885 | TOLL-LIKE RECEPTOR-7 AND -8 MODULATORY 1H IMIDAZOQUINOLINE DERIVED COMPOUNDS - The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides TLR7 agonists and TLR7/TLR8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof. Derivatives of the imidazoquinoline derived compounds also include dendrimers and dimers of the imidazoquinoline derived compounds, and methods of making and using the dendrimeic and dimeric imidazoquinoline derived compounds. The present disclosure also provides dual TLR2/TLR7 hybrid agonists that include imidazoquinoline derived compounds of the present disclosure. | 11-22-2012 |
20120272868 | PRODUCTION OF GRAPHENE NANORIBBONS WITH CONTROLLED DIMENSIONS AND CRYSTALLOGRAPHIC ORIENTATION - Graphene particulates, especially graphene nanoribbons (GNRs) and graphene quantum dots Ds and and a high-throughput process for the production of such particulates is provided. The graphene particulates are produced by a nanotomy process in which graphene blocks are cut from a source of graphite and then exfoliated into a plurality of graphene particulates. Graphene particulates having narrow widths, on the order of 100 nm or less, can be produced having band gap properties suitable for use in a variety of electrical applications. | 11-01-2012 |
20120271201 | DEVICE, SYSTEM, AND METHOD FOR DETERMINATION OF ORAL/LIP STIFFNESS - A device for measuring orofacial stiffness in a subject can include: two lip saddle attachment components configured for attachment to the lip saddles of a patients mouth; two elongate members, each being coupled with one of the lip saddle attachment components; a pivot member that couples the two elongate members at a pivot point opposite from the two lip saddle attachment components; an electronic sensor configured to sense the stiffness of the lips by sensing movement of the elongate members with respect to the pivot point, where the electronic sensor is operably coupled to each of the elongate members; and a pressure component configured move with respect to the pivot point so as to provide pressure to and/or receive pressure from the lip saddle attachment components. | 10-25-2012 |
20120226007 | HIGH CAPACITY MAGNETIC NANOPARTICLES AS SUPPORTS FOR REAGENTS AND CATALYSTS - A magnetic particle-polymer hybrid material can include: a substance having a structure of Z-(Y-Triazole-X-(FP) | 09-06-2012 |
20120225849 | 2-Methoxyestradiol (2-ME2) Prodrug with Enhanced Bioavailability for Prophylaxis or Treatment of Cancerous or Non-Cancerous Condition - A prodrug of 2-methoxyestradiol (2-ME | 09-06-2012 |
20120142637 | PRODRUGS OF 6-CYCLOHEXYL-1-HYDROXY-4-METHYLPYRIDIN-2-(1H)- ONE AND DERIVATIVES THEREOF - A prodrug can have a structure of Formula 10 or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, cancer, dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, | 06-07-2012 |
20110301311 | SILICA-SUPPORTED OLIGOMERIC HYBRID MATERIALS - A particle-polymer hybrid material can include: a substance having the structure of Formula 1 (Z—(Y—FP) | 12-08-2011 |
20110275043 | SYSTEMS AND METHODS FOR FACILITATING GAIT TRAINING - In one embodiment a gait training system includes a patient interface adapted to attach to a patient's thigh, the patient interface defining a channel, a cord that passes through the channel of the patient interface, and connecting means attached to a first end of the cord for connecting the cord to the patient's forefoot, wherein pulling of the cord pulls the patient interface forward and upward to emulate hip flexion and simultaneously pulls the connecting means upward to emulate ankle dorsiflexion. | 11-10-2011 |
20100047343 | MULTIPARTICULATE FORMULATION HAVING TRAMADOL IN IMMEDIATE AND CONTROLLED RELEASE FORM - A multi-particulate pharmaceutical composition of rapid release particles and controlled release particles comprising tramadol or a salt thereof is provided. The composition provides a rapid and controlled release of tramadol or a salt thereof in a substantially pH independent manner after oral administration to a subject. The composition can be included in a capsule, caplet, sachet, or other solid dosage form adapted to retain and then release solid pharmaceutical compositions. | 02-25-2010 |
20090081295 | NANOCLUSTERS FOR DELIVERY OF THERAPEUTICS - The present invention discloses a nano-cluster that includes a plurality of nano-particles, wherein the nano-particles can disperse in response to an environmental cue. Also disclosed is a method of preventing, treating, or diagnosing a disease or condition in a subject comprising administering a therapeutically effective amount of a composition comprising nano-clusters of the present invention. | 03-26-2009 |
20090053316 | NANOCLUSTERS FOR DELIVERY OF THERAPEUTICS - The present invention discloses a nano-cluster that includes a plurality of nano-particles, wherein the nano-particles can disperse in response to an environmental cue. Also disclosed is a method of preventing, treating, or diagnosing a disease or condition in a subject comprising administering a therapeutically effective amount of a composition comprising nano-clusters of the present invention. | 02-26-2009 |